Nonclassical biological activities of quinolone derivatives

Journal of Pharmacy and Pharmaceutical Sciences

Volumn 15, Issue 1, 2011, Pages 52-72

  Ahmed, Abeer ^a   Daneshtalab, Mohsen ^a  

^a MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

1 [5 (4 FLUOROBENZYL) 2 FURYL] 3 (1,2,4 TRIAZOL 3 YL) 1,3 PROPANEDIONE; 6 FLUORO 7 (4 HYDROXYPHENYL) 1 CYCLOPROPYL 4 QUINOLONE 3 CARBOXYLIC ACID; 6,8 DIFLUORO 7 (4' HYDROXYPHENYL) 1 CYCLOPROPYL 4 QUINOLONE 3 CARBOXYLIC ACID; 8 DIFLUOROMETHOXY 1 ETHYL 6 FLUORO 1,4 DIHYDRO 7 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL] 4 OXOQUINOLINE 3 CARBOXYLIC ACID; 9 BENZYL 7 FLUORO 3 HYDROXYTHIENO [4,5 B]QUINOLINE 4(9H) ONE; A 782759; ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; CILUPREVIR; CP 115953; CP 115955; CP 67804; DACTINOMYCIN; DNA TOPOISOMERASE (ATP HYDROLYSING); DOXORUBICIN; ELVITEGRAVIR; FZ 41; GS 9160; INTEGRASE INHIBITOR; INTERFERON; LEVOFLOXACIN; MESSENGER RNA; MITOXANTRONE; N (4 FLUOROBENZYL) 8 HYDROXY 5 (TETRAHYDRO 2H 1,2 THIAZIN 2 YL) 1,6 NAPHTHYRIDINE 7 CARBOXAMIDE S,S DIOXIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; QUINOLONE DERIVATIVE; ROSOXACIN; RUFOCROMOMYCIN; STAT3 PROTEIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIRUS RNA; VOSAROXIN;

ANTIBACTERIAL ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; CHEMICAL MODIFICATION; CHEMICAL REACTION; CLINICAL TRIAL (TOPIC); DNA SUPERCOILING; DRUG CYTOTOXICITY; DRUG DESIGN; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG POTENTIATION; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; EUKARYOTE; HEPATITIS C VIRUS; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; MALIGNANT NEOPLASTIC DISEASE; MAMMAL CELL; MOLECULAR DOCKING; MOLECULAR INTERACTION; MOLECULAR MECHANICS; MOLECULAR MODEL; NONHUMAN; PHARMACOPHORE; REACTION ANALYSIS; REVIEW; STRUCTURE ACTIVITY RELATION; VIRUS DNA CELL DNA INTERACTION;

EID: 84856190901     PISSN: None     EISSN: 14821826     Source Type: Journal    
DOI: 10.18433/j3302n     Document Type: Review

References (132)

1. Letafat B, Emami S, Mohammadhosseini N, Faramarzi MA, Samadi N, Shafiee A, Foroumadi A. Synthesis and antibacterial activity of new N-[2-(thiophen-3-yl)ethyl] piperazinyl quinolones. Chem Pharm Bull (Tokyo), 2007; 55:894-898.
2. Srivastava BK, Solanki M, Mishra B, Soni R, Jayadev S, Valani D, Jain M, Patel PR. Synthesis and antibacterial activity of 4,5,6,7-tetrahydrothieno[3,2-c]pyridine quinolones. Bioorg Med Chem Lett, 2007; 17:1924-1929.
3. Wang JC. DNA topoisomerases. Annu Rev Biochem, 1985; 54:665-697.
4. Okumura R, Hirata T, Onodera Y, Hoshino K, Otani T, Yamamoto T. Dual-targeting properties of the 3-aminopyrrolidyl quinolones, DC-159a and sitafloxacin, against DNA gyrase and topoisomerase IV: Contribution to reducing in vitro emergence of quinolone-resistant streptococcus pneumoniae. J Antimicrob Chemoth, 2008; 62:98-104.
5. O'Brien RJ. Development of fluoroquinolones as first-line drugs for tuberculosis--at long last. Am J Resp Crit Care, 2003; 168:1266-1268.
6. Janin Y L. Antituberculosis drugs: Ten years of research. Bioorg Med Chem, 2007; 15:2479-2513.
7. Mdluli K, Ma Z. Mycobacterium tuberculosis DNA gyrase as a target for drug discovery. Infect Disord Drug Targets, 2007; 7:159-68.
8. Gould RG, Jacobs WA. J Am Chem Soc, 1939; 61:2890-2895.
9. Lappin GR. Cyclization of 2-aminopyridine derivatives. I. substituted ethyl 2-pyridyl amino methylenemalonates. J Am Chem Soc, 1948; 70:3348-3350.
10. Grohe K, Heitzer H. Cycloacylation of Enamines, I.-Synthesis of 4-Quinolone-3-carboxylic Acids. Liebigs Ann Chem, 1987; 1:29-37.
11. Cecchetti V, Fravolini A, Lorenzini MC, Tabarrini O, Terni P, Xin T. Studies on 6-amino quinolones: Synthesis and antibacterial evaluation of 6-amino-8-methylquinolones. J Med Chem, 1996; 39:436-445.
12. Torii S, Okumoto H, He Xu L. A direct approach to 2-substituted 1,4 dihydro-4-oxo-quinoline-3-carboxylates by palladium-catalyzed carbonylative cyclization. Tetrahedron Lett, 1990; 31: 7175-7178.
13. Willmott C, Critchlow S, Eperon I, Maxwell A. The complex of DNA gyrase and quinolone drugs with DNA forms a barrier to transcription by RNA polymerase. J Mol Biol, 1994; 242:351-363.
14. Gómez-Eichelmann MC, Camacho-Carranza R. DNA supercoiling and topoisomerases in escherichia coli. Rev Latinoam Microbio, 1995;37:291-304.
15. Zechiedrich EL, Khodursky AB, Bachellier S, Schneider R, Chen D, Lilley DM, Cozzarelli NR. Roles of topoisomerases in maintaining steadystate DNA supercoiling in escherichia coli. J Biol Chem, 2000; 275:8103-8113.
16. Couturier M, Bahassiel M, Van Melderen L. Bacterial death by DNA gyrase poisoning. Trends Microbiol, 1998; 6:269-275.
17. Gore J, Bryant Z, Stone MD, Nöllmann M, Cozzarelli NR, Bustamante C. Mechanochemical analysis of DNA gyrase using rotor bead tracking. Nature, 2006; 439:100-104.
18. Gootz, T. D.; Brighty, K. E., In the Quinolones, (Ed. V. T. Andriole), Academic Press, San Diego, 29, 1998.
19. Morrison A, Cozzarelli NR. Site-specific cleavage of DNA by E. coli DNA gyrase. Cell, 1979; 17:175-184.
20. Llorente B, Leclerc F, Cedergren R. Using SAR and QSAR analysis to model the activity and structure of the quinolone-DNA complex. Bioorg Med Chem, 1996; 4:61-71.
21. Domagala JM. Structure-activity and structure side-effect relationships for the quinolone anti bacterials. J Antimicrob Chemother, 1994; 33:685-706.
22. Tillotson G S. Quinolones: Structure-activity relationships and future predictions. J Med Microbiol, 1996; 44:320-324.
23. Yoshida T, Yamamoto Y, Orita H, et al. Studies on quinolone antibacterials. IV. Structure-activity relationships of antibacterial activity and side effects for 5-or 8-substituted and 5,8-disubstituted-7(3-amino-1-pyrrolidinyl)-1-cyclopropyl-1,4-dihydro-4-oxoquinoline-3-carboxylic acids. Chem Pharm Bull (Tokyo), 1996; 44:1074-1085.
24. Ledoussal B, Almstead JK, Flaim CP. Novel fluoroquinolone, structure activity, and design of new potent and safe agents. In: Program and abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy (San Francisco). Washington, DC: American Society for Microbiology, 1999.
25. Ma Z, Chu DT, Cooper CS, et al. Synthesis and antimicrobial activity of 4(H)-4-oxoquinolizine derivatives: consequences of structural modification at the C-8 position. J Med Chem, 1999; 42: 4202-4213.
26. Wentzell L, Maxwell A. The complex of DNA gyrase and quinolone drugs on DNA forms a barrier to the T7 DNA polymerase replication complex. J Mol Biol, 2000; 304:779-791.
27. Shea ME, Hiasa H. Distinct effects of the UvrD helicase on topoisomerase-quinolone-DNA ternary complexes. J Biol Chem, 2000; 275:14649-14658.
28. Yoshida H, Bogaki M, Nakamura M, Nakamura S. Quinolone resistance-determining region in the DNA gyrase gyrA gene of Escherichia coli. Antimicrob Agents Chemother, 1990; 34:1271-2.
29. Piddock LJV. Mechanisms of fluoroquinolone resistance: An update 1994-1998. Drugs, 1999; 58:11-18.
30. Heddle J, Barnard F, Wentzell L, Maxwell A. The interaction of drugs with DNA gyrase: A model for the molecular basis of quinolone action. Nucleosides, Nucleotides Nucleic Acids, 2000; 19:1249-1264.
31. Palù G, Valisena S, Ciarrocchi G, Gatto B, Palumbo M. Quinolone binding to DNA is mediated by magnesium ions. Proc Natl Acad Sci U. S. A., 1992; 89:9671-9675.
32. Sissi C, Perdonà E, Domenici E, Feriani A, Howells A, Maxwell A, Palumbo, M. Ciprofloxacin affects conformational equilibria of DNA gyrase A in the presence of magnesium ions. J Mol Biol, 2001; 311:195-203.
33. Shen, LL, Pernet AG. Mechanism of inhibition of DNA gyrase by analogues of nalidixic acid: The target of the drugs is DNA. Proc Natl Acad Sci U. S. A., 1985; 82:307-311.
34. Critchlow SE, Maxwell A. DNA cleavage is not required for the binding of quinolone drugs to the DNA gyrase-DNA complex. Biochemistry, 1996; 35:7387-7393.
35. Kampranis SC, Maxwell A. The DNA gyrasequinolone complex. ATP hydrolysis and the mechanism of DNA cleavage. J Biol Chem, 1998; 273:22615-22626.
36. Chen GL, Yang L, Rowe TC, Halligan BD, Tewey KM, Liu, LF. Nonintercalative antitumor drugs interfere with the breakage-reunion reaction of mammalian DNA topoisomerase II. J Biol Chem, 1984; 259:13560-13566.
37. Woese CR. Bacterial evolution. Microbiol Rev, 1987; 51:221-271.
38. Forterre P, Nadal M, Elie C, Mirambeau G, Jaxel C, and Duguet M. Mechanisms of DNA synthesis and topoisomerisation in archaebacteria; reverse gyration in vitro and in vivo. System Appl Microbiol, 1986; 7:67-71.
39. Sioud M, Forterre P. Ciprofloxacin and etoposide (VP16) produce a similar pattern of DNA cleavage in a plasmid of an archaebacterium. Biochemistry, 1989; 28:3638-3641.
40. Ryckebusch A, Garcin D, Lansiaux A, Goossens J, Baldeyrou B, Houssin R, Bailly C, Hénichart J. Synthesis, cytotoxicity, DNA interaction, and topoisomerase II inhibition properties of novel indeno[2,1-c]quinolin-7-one and indeno[1,2-c]isoquinolin-5,11-dione derivatives. J Med Chem, 2008; 51:3617-3629.
41. Ferlin MG, Chiarelotto G, Gasparotto V, Dalla Via L, Pezzi V, Barzon L, Palù G, Castagliuolo I. Synthesis and in vitro and in vivo antitumor activity of 2-phenylpyrroloquinolin-4-ones. J Med Chem, 2005; 48:3417-3427.
42. Gasparotto V, Castagliuolo I, Chiarelotto G, Pezzi V, Montanaro D, Brun P, Palù G, Viola G, Ferlin MG. Synthesis and biological activity of 7-phenyl-6,9-dihydro-3H-pyrrolo[3,2-f]quinolin-9-ones: A new class of antimitotic agents devoid of aromatase activity. J Med Chem, 2006; 49:1910-1915.
43. Pommier Y. DNA topoisomerase I and II in cancer chemotherapy: Update and perspectives. Cancer Chemother Pharmacol, 1993; 32:103-108.
44. Bhargava R, Lal P, Chen B. HER-2/neu and topoisomerase IIa gene amplification and protein expression in invasive breast carcinomas: Chromogenic in situ hybridization and immunohistochemical analyses. Am J Clin Pathol, 2005; 123:889-895.
45. Schmidt F, Knobbe CB, Frank B, Weller M, Wolburg H. The topoisomerase II inhibitor, genistein, induces G2/M arrest and apoptosis in human malignant glioma cell lines. Oncol Rep, 2008; 19:1061-1066.
46. Richter S, Parolin C, Palumbo M, Palu G. Antiviral properties of quinolone-based drugs. Curr Drug Targets Infect Disord, 2004; 4:111-116.
47. Lock RB, Ross WE. DNA topoisomerases in cancer therapy. Anti-Cancer Drug Design, 1987; 2:151-164.
48. Schneider E, Hsiang YH, Liu LF. DNA topoisomerases as anticancer drug targets. Advances in Pharmacology (San Diego, Calif.), 1990; 21:149-183.
49. Zwelling LA. Topoisomerase II as a target of antileukemia drugs: A review of controversial areas. Hematologic Pathology, 1989; 3:101-112.
50. Kreuzer KN, Cozzarelli NR. Escherichia coli mutants thermosensitive for deoxyribonucleic acid gyrase subunit A: Effects on deoxyribonucleic acid replication, transcription, and bacteriophage growth. J Bacteriol, 1979; 140:424-435.
51. Osheroff N, Zechiedrich EL, Gale, KC. Catalytic function of DNA topoisomerase II. BioEssays: News and Reviews in Molecular, Cellular and Developmental Biology, 1991; 13:269-273.
52. Drlica K, Franco RJ. Inhibitors of DNA topoisomerases. Biochemistry, 1988; 27:2253-2259.
53. Hooper DC, Wolfson JS. Fluoroquinolone antimicrobial agents. N Engl J Med, 1991; 324: 384-94.
54. Yamashita Y, Ashizawa T, Morimoto M., et al. Antitumor quinolones with mammalian topo isomerase II mediated DNA cleavage activity. Cancer Res, 1992; 52:2818-2822.
55. Hussy P, Maass G, Tummler B, Grosse F, Schomburg U. Effect of 4-quinolones and novobiocin on calf thymus DNA polymerase alpha primase complex, topoisomerases I and II, and growth of mammalian lymphoblasts. Antimicrob Agents Chemother, 1986; 29:1073-1078.
56. Dobson RA, O'Connor JR, Poulin SA, Kundsin RB, Smith TF, Came PE. In vitro antimicrobial activity of rosoxacin against Neisseria gonorrhoeae, Chlamydia trachomatis, and Ureaplasma urealyticum. Antimicrob Agents Chemother, 1980; 18:738-740.
57. Carabateas PM, Brundage, RP, Gellote MD, Lorenz RR, Opalka CJ, Thielking WH, Williams GL, Lesher GY. 1-Ethyl-1,4-dihydro-4-oxo-7-(pyridinyl)-3-quinolinecarboxylic acids. II. Synthesis J Heterocycl Chem, 1984; 21:1857-1863.
58. Wentland MP, Lesher GY, Reuman M, Gruett M D, Singh B, Aldous, S C, et al. Mammalian topoisomerase II inhibitory activity of 1-cyclopropyl-6,8-difluoro-1,4-dihydro-7-(2,6-dimethyl-4-pyridinyl)-4-oxo-3-quinolinecarboxylic acid and related derivatives. J Med Chem, 1993; 36:2801-2809.
59. Eissenstat MA, Kuo G, Weaver JD, Wentland, MP. 3-benzyl-quinolones: Novel, potent inhibitors of mammalian topoisomerase II. Bioorg Med Chem Lett, 1995; 5:1021-1026.
60. Kohlbrenner WE, Wideburg N, Weigl D, Saldivar A, Chu, DT. Induction of calf thymus topoisomerase II-mediated DNA breakage by the antibacterial isothiazoloquinolones A-65281 and A-65282. Antimicrob Agents Chemother, 1992; 36:81-86.
61. DoganKoruznjak J, Slade N, Zamola B, Pavelić K, Karminski-Zamola G. Synthesis, photochemical synthesis and antitumor evaluation of novel derivatives of thieno[3',2':4,5]thieno[2,3-c]quinolones. Chem Pharm Bull (Tokyo), 2002; 50:656-660.
62. Robinson MJ, Martin BA, Gootz TD. Effects of quinolone derivatives on eukaryotic topoisomerase II. A novel mechanism for enhancement of enzyme-mediated DNA cleavage. J Biol Chem, 1991; 266:14585-14592.
63. Robinson MJ, Martin BA, Gootz TD, McGuirk PR, Osheroff N. Effects of novel fluoroquinolones on the catalytic activities of eukaryotic topoisomerase II: Influence of the C-8 fluorine group. Antimicrob Agents Chemother, 1992; 36:751-756.
64. Elsea SH, McGuirk PR, Gootz TD, Moynihan M, Osheroff N. Drug features that contribute to the activity of quinolones against mammalian topoisomerase II and cultured cells: Correlation between enhancement of enzyme-mediated DNA cleavage in vitro and cytotoxic potential. Antimicrob Agents Chemother, 1993; 37:2179-2186.
65. Alovero FL, Pan XS, Morris JE, Manzo RH, Fisher LM. Engineering the specificity of antibacterial fluoroquinolones: Benzenesulfonamide modifications at C-7 of ciprofloxacin change its primary target in Streptococcus pneumoniae from topoisomerase IV to gyrase. Antimicrob Agents Chemother, 2000; 44:320-325.
66. Gootz TD, McGuirk PR, Moynihan MS, Haskell SL. Placement of alkyl substituents on the C-7 piperazine ring of fluoroquinolones: Dramatic differential effects on mammalian topoisomerase II and DNA gyrase. Antimicrob Agents Chemother, 1994; 38:130-133.
67. Suto MJ, Domagala JM, Roland GE, Mailloux GB, Cohen MA. Fluoroquinolones: Relationships between structural variations, mammalian cell cytotoxicity, and antimicrobial activity. J Med Chem, 1992; 35:4745-4750.
68. Barrett JF, Gootz TD, McGuirk PR, Farrell CA, Sokolowski SA. Use of in vitro topoisomerase II assays for studying quinolone antibacterial agents. Antimicrob Agents Chemother, 1989; 33:1697-1703.
69. Advani RH, Hurwitz HI, Gordon MS, Ebbinghaus SW, Mendelson DS, Wakelee HA, et al. Voreloxin, a first-in-class anticancer quinolone derivative, in Relapsed/Refractory solid tumors: A report on two dosing schedules. Clin Canc Res, 2010; 16:2167-2175.
70. Hosomi J, Asahina Y, Suzue S. PCT Int. Appl. WO 89 12055. Preparation of thiazoloquinolonecarboxylic acid derivatives and their pharmaceutical compositions as antitumor agents (Chem Abstr. 1990, 113, 6328m), 1989.
71. Sissi C, Palumbo M. The quinolone family: From antibacterial to anticancer agents. Curr Med Chem:Anti-Cancer Agents. 2003; 3:439-450.
72. 1-alkylation of 4-quinoline-3-carboxylic acid esters using modified mitsnobu reaction. 21st International Congress for Heterocyclic Chemistry (ICHC-21) Sydney, Australia, abstract # TP-21.
73. Ahmed A, Daneshtalab, M. Polycyclic quinolones (part1)-thieno [2,3-b] benzo [h] quinoline derivatives: design, synthesis, preliminary in vitro and in silico studies. Heterocycl. Submission no. Com-11-12374.
74. Bromberg J, Darnell JE. The role of STATs in transcriptional control and their impact on cellular function. Oncogene, 2000; 19:2468-2473.
75. Levy DE, Darnell JE. STATs: transcriptional control and biological impact. Nat Rev Mol Cell Biol, 2002; 3: 651-662.
76. Klampfer L. Signal transducers and activators of transcription (STATs): novel targets of chemopreventive and chemotherapeutic drugs. Curr Cancer Drug Targets, 2006; 6:107-121.
77. Darnell JE. Validating STAT3 in cancer therapy. Nat Med, 2005; 11:595-596.
78. Jing N, Tweardy DJ. Targeting STAT3 in cancer therapy. Anti-Cancer Drugs, 2005; 16:601-607.
79. Xu J, Cole DC, Chang CPB, Ayyad R, Asselin M, Hao W, Gibbons J, Jelinsky SA, Saraf KA, Park K. Inhibition of the signal transducer and activator of transcription-3 (STAT3) signalling pathway by 4-oxo-1-phenyl-1,4-dihydro quinoline-3-carboxylic acid esters. J Med Chem, 2008; 51: 4115-4121.
80. Golub AG, Yakovenko OY, Bdzhola VG, Sapelkin, VM, Zien P, Yarmoluk, SM. Evaluation of 3-carboxy-4(1H)-quinolones as inhibitors of human protein kinase CK2. J Med Chem, 2006; 49: 6443-6450.
81. Palù G, Valisena S, Ciarrocchi G, Gatto B, Palumbo M. Quinolone binding to DNA is mediated by magnesium ions. Proc Natl Acad Sci U. S. A., 1992; 89: 9671-9675.
82. Shen LL, Pernet AG. Mechanism of inhibition of DNA gyrase by analogues of nalidixic acid: The target of the drugs is DNA. Proc. Natl. Acad. Sci. U. S. A., 1985; 82:307-311.
83. Shen LL, Kohlbrenner WE, Weigl D, Baranowski J. Mechanism of quinolone inhibition of DNA gyrase appearance of unique norfloxacin binding sites in enzyme-DNA complexes. J Biol Chem, 1989; 264:2973-2878.
84. Shen LL, Baranowski J, Pernet A G. Mechanism of inhibition of DNA gyrase by quinolone antibacterials: Specificity and cooperativity of drug binding to DNA. Biochemistry, 1989; 28:3879-3885.
85. Shen LL, Mitscher LA, Sharma PN, O'Donnell TJ, Chu DW, Cooper CS, et al. Mechanism of inhibition of DNA gyrase by quinolone antibacterials: A cooperative drug--DNA binding model. Biochemistry, 1989; 28:3886-3894.
86. Palumbo M, Gatto B, Zagotto G, Palù G. On the mechanism of action of quinolone drugs. Trends Microbiol, 1993; 1:232-5.
87. Kimura T, Katsube T. Aminoquinoline derivatives as anti-HIV agents. European patent 572259, 1993
88. Bender W, Roeben W, Paesens A, Bartel, S. WO9602540, Preparation of piperazinoquinolonecarboxylates as antiviral agents. Ger. Offen. DE 4425647 A1 19960125, 1996.
89. Bender W, Roeben W, Paesens A, Bartel S. WO9602532, Preparation of 7-piperazinyl-1,4-dihydro-4-oxo-1-[4-(1H-1,2,4-triazol-1-ylmethyl) phenyl] quinoline-3-carboxylic acids as virucides. Ger. Offen. DE 4425660 A1 19960125, 1996.
90. Nozaki-Renard J, Iino T, Sato Y, Marumoto Y, Ohta G, Furusawa M. Fluoroquinolones protect the human lymphocyte CEM cell line from HIV-1-mediated cytotoxicity. Cell Structure and Function, 1990; 15:295-299.
91. Nozaki-Renard J, Iino T, Sato Y, Marumoto Y, Ohta G, Furusawa M. A fluoroquinolone (DR-3355) protects human lymphocyte cell lines from HIV-1-induced cytotoxicity. AIDS (London, England), 1990; 4:1283-1286.
92. Baba M, Okamoto M, Makino M, Kimura Y, Ikeuchi T, Sakaguchi T, et al. Potent and selective inhibition of human immunodeficiency virus type 1 transcription by piperazinyloxoquinoline derivatives. Antimicrob Agents Chemother, 1997; 41:1250-1255.
93. Daelemans D, Vandamme AM, De Clercq E. Human immunodeficiency virus gene regulation as a target for antiviral chemotherapy. Antiviral Chem Chemother, 1999; 10:1-14.
94. Parolin C, Gatto B, Del Vecchio C, Pecere T, Tramontano E, Cecchetti V, et al. New antihuman immunodeficiency virus type 1 6-aminoquinolones: Mechanism of action. Antimicrob Agents Chemother, 2003; 47:889-896.
95. Tabarrini O, Stevens M, Cecchetti V, Sabatini S, Dell'Uomo M, Manfroni G, et al. Structure modifications of 6-aminoquinolones with potent anti-HIV activity. J Med Chem, 2004; 47: 5567-78.
96. Tabarrini O, Massari S, Daelemans D, Stevens M, Manfroni G, Sabatini S, et al. Structure-Activity relationship study on anti-HIV 6-desfluoroquinolones. J Med Chem 2008; 51:5454-5458.
97. Stevens M, Pollicita M, Pannecouque C, Verbeken E, Tabarrini O, Cecchetti V, et al. Novel in vivo model for the study of human immunodeficiency virus type 1 transcription inhibitors: Evaluation of new 6-desfluoroquinolone derivatives. Antimicrob Agents Chemother, 2007; 51:1407-1413.
98. Pommier Y, Johnson A, Marchand C. Integrase inhibitors to treat HIV/AIDS. Nat Rev Drug Discovery, 2005; 4:236-248.
99. Boros EE, Johns BA, Garvey EP, Koble CS, Miller WH. Synthesis and HIV-integrase strand transfer inhibition activity of 7-hydroxy[1,3]thiazolo[5,4-b]pyridin-5(4H)-ones. Bioorg Med Chem Lett, 2006; 16:5668-5672.
100. Cecchetti V, Parolin C, Moro S, Pecere T, Filipponi E, Calistri A, et al. 6-aminoquinolones as new potential anti-HIV agents. J Med Chem, 2000; 43:3799-802.
101. Sato M, Motomura T, Aramaki H, Matsuda T, Yamashita M, Ito, Y, et al. Novel HIV-1 integrase inhibitors derived from quinolone antibiotics. J Med Chem, 2006; 49:1506-1508.
102. Dayam R, Sanchez T, Neamati, N. Diketo acid pharmacophore. 2. discovery of structurally diverse inhibitors of HIV-1 integrase. J Med Chem, 2005; 48:8009-8015.
103. Dayam R, Al-Mawsawi LQ, Zawahir Z, Witvrouw M, Debyser Z, Neamati N. Quinolone 3-carboxylic acid pharmacophore: Design of second generation HIV-1 integrase inhibitors. J Med Chem, 2008; 51:1136-1144.
104. Machouf N, Thomas R, Nguyen V K, Trottier B, Boulassel MR, Wainberg MA, et al. Effects of drug resistance on viral load in patients failing antiretroviral therapy. J Med Virol, 2006; 78: 608-613.
105. Cozzi-Lepri A, Phillips AN, Ruiz L, Clotet B, Loveday C, Kjaer J, et al. Evolution of drug resistance in HIV-infected patients remaining on a virologically failing combination antiretroviral therapy regimen. AIDS (London, England), 2007; 21:721-732.
106. Friis-Møller N, Reiss P, Sabin CA, Weber R, Monforte A, El-Sadr W, et al. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med, 2007; 356:1723-1735.
107. Potter SJ, Lemey P, Dyer WB, Sullivan JS, Chew CB, Vandamme AM, et al. Genetic analyses reveal structured HIV-1 populations in serially sampled T lymphocytes of patients receiving HAART. Virology, 2006; 348:35-46.
108. Fätkenheuer G, Pozniak AL, Johnson MA, Plettenberg A, Staszewski S, Hoepelman AI, et al. Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1. Nat Med, 2005; 11:1170-1172.
109. Sorbera LA, Serradell N. Monographs-GS-9137-anti-HIV agent, HIV integrase inhibitor. Drugs of the Future, 2006; 31:310-313.
110. Jones GS, Yu F, Zeynalzadegan A, Hesselgesser J, Chen X, Chen, J, et al. Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase. Antimicrob Agents Chemother, 2009; 53:1194-1203.
111. Hazuda DJ, Felock P, Witmer M, Wolfe A, Stillmock K, Grobler JA, et al. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science (New York, N.Y.), 2000; 287:646-50.
112. Long YQ, Jiang, XH, Dayam R, Sanchez T, Shoemaker R, Sei S, et al. Rational design and synthesis of novel dimeric diketoacid-containing inhibitors of HIV-1 integrase: Implication for binding to two metal ions on the active site of integrase. J Med Chem, 2004; 47:2561-2573.
113. Mekouar K, Mouscadet JF, Desmaële D, Subra F, Leh H, Savouré D, et al. Styrylquinoline derivatives: A new class of potent HIV-1 integrase inhibitors that block HIV-1 replication in CEM cells. J Med Chem, 1998; 41:2846-2857.
114. Polanski J, Zouhiri F, Jeanson L, Desmaële D, d'Angelo J, Mouscadet JF, et al. Use of the kohonen neural network for rapid screening of ex vivo anti-HIV activity of styrylquinolines. J Med Chem, 2002; 45:4647-54.
115. Fujishita T, Yoshinaga T, Sato A. PCT Int. Appl. WO 2000039086A, Preparation of aromatic heterocycle compounds having HIV integrase inhibiting activities, 2000.
116. Hazuda DJ, Anthony NJ, Gomez RP, Jolly SM, Wai JS, Zhuang L, et al. A naphthyridine carboxamide provides evidence for discordant resistance between mechanistically identical inhibitors of HIV-1 integrase. Proc Natl Acad Sci U. S. A., 2004; 101:11233-11238.
117. Mousnier A, Leh H, Mouscadet J F, Dargemont C. Nuclear import of HIV-1 integrase is inhibited in vitro by styrylquinoline derivatives. Mol Pharmacol, 2004; 66:783-788.
118. Zouhiri F, Desmaele D, d'Angelo J, Ourevitch M, Mouscadet JF, Leh H, et al. HIV-1 replication inhibitors of the styrylquinoline class: Incorporation of a masked diketo acid pharmacophore. Tetrahedron Lett, 2001; 42:8189-8192.
119. Majerz-Maniecka K, Musiol R, Nitek W, et al. Intermolecular interactions in the crystal structures of potential HIV-1integrase inhibitors. Bioorg Med Chem Lett, 2006; 16:1005-1009.
120. Adam MM, Bats JW, Nikolaus NV, Witvrouw M, Debyser Z, Engels JW. Microwave-assisted synthesis of fluoroquinolones and their nucleosides as inhibitors of HIV integrase. Collect Czech Chem Commun, 2006; 71:978-990.
121. Pasquini S, Mugnaini C, Tintori C, Botta M, Corelli F, Trejos A, et al. Investigations on the 4-quinolone-3-carboxylic acid motif. 1. synthesis and structure-activity relationship of a class of human immunodeficiency virus type 1 integrase inhibitors. J Med Chem, 2008; 51:5125-5129.
122. Barreca ML, De Luca L, Iraci N, Chimirri A. Binding mode prediction of strand transfer HIV-1 integrase inhibitors using Tn5 transposase as a plausible surrogate model for HIV-1 integrase. J Med Chem, 2006; 49:3994-3997.
123. Rönn R, Sandström A. New developments in the discovery of agents to treat Hepatitis C. CurrTopMed Chem, 2008; 8:633-562.
124. Reed K E, Rice CM. Expression and characterization of the HCV NS2 protease. Methods in Molecular Medicine, 1999; 19:331-342.
125. Pallaoro M, Lahm A, Biasiol G, Brunetti M, Nardella C, Orsatti L, et al. Characterization of the hepatitis C virus NS2/3 processing reaction by using a purified precursor protein. J Virol, 2001; 75:9939-46.
126. Kumar DV, Rai R, Brameld KA, Somoza JR, Rajagopalan R, Janc JW, et al. Quinolones as HCV NS5B polymerase inhibitors. Bioorg Med Chem Lett, 2011; 21:82-87.
127. Kolykhalov AA, Mihalik K, Feinstone SM, Rice CM. Hepatitis C virus-encoded enzymatic activities and conserved RNA elements in the 3' nontranslated region are essential for virus replication in vivo. J Virol, 2000; 74:2046-51.
128. Kneteman NM, Howe AYM, Gao T, Lewis J, Pevear D, Lund G, et al. HCV796: A selective nonstructural protein 5B polymerase inhibitor with potent anti-hepatitis C virus activity in vitro, in mice with chimeric human livers, and in humans infected with hepatitis C virus. Hepatology, 2009; 49:745-752.
129. thAnnual Meeting of AASLD. Hepatology 40 (S4), 697A (Abstract 1224a), 2004.
130. Lu L, Pilot-Matias TJ, et al. Mutations conferring resistance to a potent hepatitis C virus serine protease inhibitor in vitro. Antimicrob Agents Chemother, 2004; 48:2260-2266.
131. Mo H, Lu L, et al. Mutations conferring resistance to a hepatitis C virus (HCV) RNAdependent RNA polymerase inhibitor alone or in combination with an HCV serine protease inhibitor in vitro. Antimicrob Agents Chemother, 2005; 49:4305-4314.
132. Koev G, Dekhtyar T, Han L, Yan P, Ng TI, Lin CT, et al. Antiviral interactions of an HCV polymerase inhibitor with an HCV protease inhibitor or interferon in vitro. Antiviral Res, 2007; 73:78-83.